{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gammaplex+%285%25%29&page=3",
    "query": {
      "intervention": "Gammaplex (5%)",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 78,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gammaplex+%285%25%29&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gammaplex+%285%25%29&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T11:56:27.650Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00666263",
      "title": "Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multifocal Motor Neuropathy"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (human), 10%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "0.25% human albumin solution (Placebo)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2008-08-22",
      "completion_date": "2011-08-11",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Stanford, California • Centennial, Colorado + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00666263"
    },
    {
      "nct_id": "NCT00343785",
      "title": "Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2006-02",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2017-04-13",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 3,
      "location_summary": "Salt Lake City, Utah • Seattle, Washington • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343785"
    },
    {
      "nct_id": "NCT02176863",
      "title": "Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Post-polio Syndrome"
      ],
      "interventions": [
        {
          "name": "Flebogamma® 5% DIF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Instituto Grifols, S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 191,
      "start_date": "2014-09-23",
      "completion_date": "2022-11-24",
      "has_results": true,
      "last_update_posted_date": "2025-12-05",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 4,
      "location_summary": "St Louis, Missouri • Syracuse, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176863"
    },
    {
      "nct_id": "NCT02013037",
      "title": "The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Antibody-mediated Rejection",
        "Hyperacute Rejection of Cardiac Transplant",
        "Left Ventricular Dysfunction",
        "Cardiac Allograft Vasculopathy",
        "Heart Graft Dysfunction"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-11",
      "completion_date": "2020-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-05-03",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02013037"
    },
    {
      "nct_id": "NCT02130817",
      "title": "Belatacept in Kidney Transplantation of Moderately Sensitized Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Antibody Mediated Rejection"
      ],
      "interventions": [
        {
          "name": "Belatacept",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus withdrawal",
          "type": "DRUG"
        },
        {
          "name": "Plasmapheresis/Intravenous Immunoglobulin G",
          "type": "PROCEDURE"
        },
        {
          "name": "Thymoglobulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "Myfortic",
          "type": "DRUG"
        },
        {
          "name": "Steroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2014-09-24",
      "completion_date": "2015-10-09",
      "has_results": false,
      "last_update_posted_date": "2018-12-17",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02130817"
    },
    {
      "nct_id": "NCT05662228",
      "title": "Therapies for Down Syndrome Regression Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Down Syndrome",
        "Regression"
      ],
      "interventions": [
        {
          "name": "Lorazepam",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulin (IVIG)",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "8 Years to 30 Years"
      },
      "enrollment_count": 66,
      "start_date": "2023-06-29",
      "completion_date": "2026-05-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Aurora, Colorado",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05662228"
    },
    {
      "nct_id": "NCT00389324",
      "title": "A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunologic Deficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "13 Years to 75 Years"
      },
      "enrollment_count": 35,
      "start_date": "2006-11",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2015-04-20",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 6,
      "location_summary": "Irvine, California • Los Angeles, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00389324"
    },
    {
      "nct_id": "NCT04480424",
      "title": "Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "GAMUNEX-C",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard Medical Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-09-17",
      "completion_date": "2021-10-25",
      "has_results": true,
      "last_update_posted_date": "2022-10-07",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 18,
      "location_summary": "Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480424"
    },
    {
      "nct_id": "NCT07674745",
      "title": "Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "Therapeutic Plasma Exchange",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Intravenous immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Treatment as Usual",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 52,
      "start_date": "2026-10-01",
      "completion_date": "2031-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07674745"
    },
    {
      "nct_id": "NCT05952804",
      "title": "IVIG for Infection Prevention After CAR-T-Cell Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Infusion (Human), 10% Solution",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Anti-CD19 CAR T Cells Preparation",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Electronic Health Record Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2024-06-10",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-10T11:56:27.650Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Miami, Florida • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05952804"
    }
  ]
}